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Depressive disorders account for a large and increasing global burden of disease. Although the condition of many
patients improves with medication, only a minority experience full remission, and patients whose condition responds
to one medication may not have a response to others. Individual variation in antidepressant treatment outcome is,
at present, unpredictable but may have a partial genetic basis. We searched for genetic predictors of treatment out-
come in 1,953 patients with major depressive disorder who were treated with the antidepressant citalopram in
the Sequenced Treatment Alternatives for Depression (STAR*D) study and were prospectively assessed. In a split-
sample design, a selection of 68 candidate genes was genotyped, with 768 single-nucleotide–polymorphism markers
chosen to detect common genetic variation. We detected significant and reproducible association between treatment
outcome and a marker in HTR2A (P range to in the total sample). Other markers in HTR2A56 551# 10 3.7# 10
also showed evidence of association with treatment outcome in the total sample. HTR2A encodes the serotonin
2A receptor, which is downregulated by citalopram. Participants who were homozygous for the A allele had an
18% reduction in absolute risk of having no response to treatment, compared with those homozygous for the other
allele. The A allele was over six times more frequent in white than in black participants, and treatment was less
effective among black participants. The A allele may contribute to racial differences in outcomes of antidepressant
treatment. Taken together with prior neurobiological findings, these new genetic data make a compelling case for
a key role of HTR2A in the mechanism of antidepressant action.
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Major depressive disorder (MDD) is a major public
health problem and a frequent reason why patients visit
internists, family practitioners, psychiatrists, and other
physicians.1 MDD constitutes the fourth greatest dis-
ease burden worldwide, measured in disability-adjusted
life years, which express years of healthy life lost to
death and disability.2 MDD is predicted to account for
the second greatest global disease burden by 2020.3
Many patients can expect their condition to improve
with antidepressant treatment, but only a minority ex-
perience full remission, and individual outcomes differ
across medications. The largest study to date demon-
strated that up to 63% of patients have improvement
and that 47% of patients achieve complete remission of
symptoms after an adequate trial with a single antide-
pressant.4 Patients whose treatment is unsuccessful with
one antidepressant medication often have a response
when treated with an antidepressant of a different chem-
ical class (reviewed by Marangell5).
Little is known about the basis for such marked indi-
vidual variation in treatment outcome. Indirect evidence
suggests that at least some of this variation has a genetic
basis.6 Outcome and side-effect patterns vary less be-
tween illness episodes than between individuals in some
studies7,8 but not all.9 Other studies have shown that
outcome of antidepressant treatment runs in families.8,
10 It has been suggested that a number of genetic variants
influence outcome and/or side effects in comparatively
small, naturalistic samples of patients treated for major
depression, but these findings have often not been rep-
licated (reviewed by Franchini et al.8 and Malhotra et
al.11). Since the effects of individual genes may be small,
the definitive identification of alleles involved in anti-
depressant-treatment outcome may require large, well-
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Figure 1 CONSORT chart of genotyping and analysis of
STAR*D sample. Samples dropped from analysis comprised 34 sub-
jects who were noncompliant with medications, 19 with initial QIDS-
C16 !10 or missing, 5 with missing clinical data, 4 whose molecular
and recorded sex did not match, and 3 duplicate samples.
characterized samples.
The Sequenced Treatment Alternatives for Depression
(STAR*D) study collected DNA from 1,953 subjects with
MDD. At the first treatment step, participants received
the selective serotonin reuptake inhibitor (SSRI) citalo-
pram, with regular assessment of outcome and side ef-
fects.12 A genetic association study of phenotypes mea-
suring outcome of citalopram treatment was undertaken
in the STAR*D sample, with use of 768 markers selected
to detect common sequence variation within each of 68
candidate genes.
Methods
Sample
The rationale, methods, and design of the STAR*D study have
been detailed elsewhere.13 In brief, investigators at 14 regional
centers across the United States implemented a standard study
protocol at 41 clinical sites.
Subjects provided separate written informed consent for study
participation and for the collection of blood samples for ge-
netic studies. Outpatients aged 18–75 years with a baseline
Hamilton Depression Rating Scale score14,15 of 14 who met
DSM-IV16 criteria for nonpsychotic MDD were eligible. Pa-
tients with bipolar, psychotic, or obsessive-compulsive disor-
ders were excluded, as were those with primary eating dis-
orders, general medical conditions that contraindicated study
medications, substance dependence requiring inpatient detox-
ification, and clear nonresponse or intolerance to any protocol
antidepressant during current episode or those who were preg-
nant or breast-feeding.
The 16-item Quick Inventory of Depressive Symptomatol-
ogy–Clinician-rated (QIDS-C16)
12,13,17,18 was obtained at base-
line and at each treatment visit, to measure symptom severity.
The intraclass correlation coefficient for the QIDS-C16, repeated
across raters over 4 years, was 0.96 (A.J.R.’s unpublished
data). Patients with a baseline QIDS-C16 110 were eligible if
the treating clinician determined that outpatient treatment with
an antidepressant medication was indicated and safe. At level
1, the protocol required an adequate dose of citalopram for a
sufficient time to maximize the likelihood of treatment success,
to ensure that those who did not improve were most likely
unresponsive to the medication, not just underdosed.12 No con-
comitant medications were allowed, aside from benzodiaze-
pines and hypnotics if needed. A CONSORT (Consolidated
Standards of Reporting Trials) diagram of the current study
sample is shown in figure 1.
DNA Samples
DNA samples were collected from 1,953 participants. A sam-
ple of 20 ml of whole blood was collected in citrate-treated
vacuum tubes and was shipped overnight to the Rutgers Cell
Repository, where lymphocytes were extracted and cryopre-
served using standard methods. DNA was extracted using Gene-
Pure chemistry (Qiagen) and was shipped on dry ice to the
NIH laboratories. Samples were arrayed using a Tecan Genesis
robot (Lipsky Lab), then sex-verified with a set of three X-
linked and two Y-linked markers (McMahon Lab). Four sex
discrepancies were identified and were excluded before samples
were genotyped further.
A summary of the sample characteristics is shown in table
1. Those who consented to have blood drawn were similar to
those in the full study sample but showed slight differences in
several variables that reached statistical significance because of
the large sample size. Subjects who consented to have blood
drawn were older and better educated, with higher household
income, and were more likely to be married, to be retired, and
to describe themselves as white. These subjects were also more
likely to come from a primary-care setting and to report more
time elapsed since their first major depressive episode (MDE),
more episodes, and greater comorbidity. These differences can-
not affect the genetic association results, which derive from
comparisons among the genotyped subjects. However, these
differences may limit the generalizability of our findings, and
clinical outcomes in the genotyped sample may differ some-
what from those in the full STAR*D sample.12
Phenotypes
All phenotype definitions and assignments were settled in
advance and were assigned before genotyping. Patients were
scored for treatment outcome in two ways: designated remis-
sion and response (fig. 2). In the absence of external validators,
our choice of categorical phenotypes was guided (1) by careful
work with the STAR*D clinicians—in advance of the geno-
typing—to develop distinctions that had face validity and took
advantage of the large body of data available from the STAR*D
trial; (2) by ensuring maximal contrast between the outcome
groups, to improve power, and creating “probable” groups
that approximated the more narrowly defined categories, to
test their robustness; (3) and by paying special attention to full
remission of symptoms, since this was the primary target out-
come of treatment.
Remitters achieved a QIDS-C16 score of 5 at the last treat-
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Table 1
Selected Demographic and Clinical Characteristics of the STAR*D Sample
CHARACTERISTIC
COMPLETE
SAMPLE
( )Np 4,041
PATIENTS WITH BLOOD DRAWN COMPARISON
Yes
( )np 1,953
No
( )np 2,088 Test Statistica df Pb
Sociodemographic:
Mean (SD) age (years) 40.5  13.3 42.7  13.4 38.4  12.9 t p 10.31 4,037 !.0001
Sex: x2 p 1.48 1 NS
Male 1,509 (37.3) 748 (38.3) 761 (36.4)
Female 2,532 (62.7) 1,205 (61.7) 1,327 (63.6)
Race: x2 p 13.20 2 .0014
White 3,055 (75.7) 1,526 (78.2) 1,529 (73.4)
Black 709 (17.6) 313 (16.0) 396 (19.0)
Other/mixed 272 (6.7) 113 (5.8) 159 (7.6)
Mean (SD) no. of years of education 13.4  3.2 13.6  3.2 13.3  3.2 x2 p 13.01 1 .0003
Employment: x2 p 19.65 2 !.0001
Employed 2,311 (57.3) 1,092 (55.9) 1,219 (58.6)
Unemployed 1,489 (36.9) 715 (36.6) 774 (37.2)
Retired 234 (5.8) 146 (7.5) 88 (4.2)
Mean (SD) monthly household income (U.S. $) 2,419  3,143 2,521  3,202 2,318  3,082 x2 p 6.23 1 .0125
Medical insurance: x2 p .68 2 NS
Private 2,022 (51.8) 998 (52.4) 1,024 (51.2)
Public 553 (14.2) 270 (14.2) 283 (14.1)
None 1,332 (34.1) 638 (33.5) 694 (34.7)
Marital status: x2 p 15.12 3 .0017
Single 1,207 (29.9) 545 (27.9) 662 (31.8)
Married/cohabiting 1,663 (41.2) 838 (42.9) 825 (39.6)
Divorced/separated 1,037 (25.7) 493 (25.2) 544 (26.1)
Widowed 128 (3.2) 77 (3.9) 51 (2.4)
Clinical:
Mean (SD) age at first MDE (years) 25.5  14.4 26.1  14.9 24.9  13.9 x2 p 3.40 1 NS
Mean (SD) time since first MDE (years) 15.0  13.1 16.6  13.9 13.5  12.1 x2 p 42.07 1 !.0001
Mean (SD) no. of MDEs 5.9  11.4 6.4  12.5 5.4  10.2 x2 p 11.09 1 .0009
Suicide ever attempted: x2 p 6.26 1 .0123
Yes 667 (16.5) 293 (15.0) 374 (17.9)
No 3,370 (83.5) 1,659 (85.0) 1,711 (82.1)
No. of psychiatric comorbidities: x2 p 24.39 4 !.0001
0 1,510 (38.2) 781 (40.9) 729 (35.7)
1 1,028 (26.0) 510 (26.7) 518 (25.4)
2 607 (15.4) 282 (14.8) 325 (15.9)
3 342 (8.7) 133 (7.0) 209 (10.2)
4 465 (11.8) 204 (10.7) 261 (12.8)
Current episode:
Clinical setting: x2 p 29.97 1 !.0001
Primary 1,575 (39) 846 (43.3) 729 (34.9)
Specialty 2,466 (61) 1,107 (56.7) 1,359 (65.1)
Mean (SD) duration of current episode (mo) 24.5  52.0 24.8  53.1 24.3  51.0 x2 p .78 1 .3764
HDRS-17c 18.8  6.5 18.4  6.2 19.6  6.9 t p 1.65 330 .099
QID-S16 13.8  4.2 13.4  4.1 14.5  4.5 t p 2.20 373 .0283
NOTE.—All data are no. (%) of patients, unless otherwise indicated.
a t p Absolute value of Student’s t test; x2 p x2 test or Kruskal-Wallis results when variables are continuous.
b NS p nonsignificant at the level.P ! .05
c 17-item Hamilton Depression Rating Scale.14,15
ment visit; probable remitters achieved a score of 6 or 7. Non-
remitters had a QIDS-C16 score of 10 at the last visit. Those
with a final QIDS-C16 score in the borderline range of 8 and
9 were excluded from analysis.
Responders achieved at least a 50% reduction in base-
line QIDS-C16 at the last treatment visit; probable respond-
ers achieved a 45%–50% reduction. Nonresponders did not
achieve even a 40% reduction in baseline QIDS-C16 score at
the last treatment visit. Those with a reduction in QIDS-C16
in the borderline range of 40%–45% were excluded from
analysis.
Only patients who completed at least 6 wk of treatment
were included in the primary analysis. Patients who achieved
the required QIDS-C16 scores after !6 wk of treatment but who
received at least 3 wk of treatment were assigned to the ap-
propriate outcome group but were classified as “probable.”
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Figure 2 Treatment-outcome phenotypes. Subjects who com-
pleted at least 6 wk of treatment with citalopram were assigned a
remission and response phenotype that was based on the QIDS-C16
score at the last treatment visit. Those who met score criteria for
remission or response after 3–6 wk of treatment were grouped with
probable remitters or probable responders, respectively.
Table 2
List of Genes Screened
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Those who did not complete at least 3 wk of treatment were
excluded from analysis. Similarly, subjects who were classified
as “intolerant” or “probably intolerant” were removed from
the nonremitter and nonresponder groups but were retained
in the remitter and responder groups, since intolerant subjects
were probably not able to take the full effective dose of ci-
talopram but might have responded if they had. Assessment
of tolerability is discussed below. Subjects who did not adhere
to the treatment regimen were excluded from analysis.
As a secondary test, relative change in QIDS-C16 score at
the last visit (expressed as percentage change from initial score)
was tested as a quantitative trait, after removal of intolerant
and nonadherent subjects.
Tolerability
Medication tolerability comprises an individual’s objective
and perceived side-effect burden and typically increases over
time and with response to treatment.19 Since failure to consider
tolerability could lead to misclassification of intolerant patients
as nonresponders, we scored all subjects as tolerant, probably
tolerant, intolerant, or probably intolerant on the basis of an
algorithm that considered study exit data and the Global Rat-
ing of Side Effect Burden (GRSEB).13 In brief, all subjects who
elected to continue citalopram at the end of the level 1 treat-
ment period were considered tolerant, whereas subjects who
refused to continue citalopram or who left the study because
of side effects were considered intolerant. The remaining sub-
jects were classified on the basis of GRSEB score into probably
tolerant (no more than moderate side effects) or probably in-
tolerant (more than moderate side effects). A small number of
subjects with missing GRSEB scores were classified according
to whether they took citalopram for !4 wk (probably intol-
erant) or 4 wk (probably tolerant).
Candidate Genes
Sixty-eight genes were chosen for study from among a larger
list of plausible candidates. Genes primarily involved in drug
metabolism were excluded, by prior agreement, since these will
be studied by another group using the same set of DNA sam-
ples. Genes were scored by an expert panel (D.C., W. Drevets,
H.M., and F.J.M.) on the basis of (1) prior evidence of asso-
ciation with antidepressant outcome (1–3 points), (2) prior evi-
dence of association with major mood disorders (1–3 points),
and (3) known functional variant(s) (0–1 points). Under this
scoring system, candidate genes could receive 0–7 points; higher
scores conferred higher priority for study. Genes with a score
of 4 were used to seed sets of related genes broadly encom-
passing five main pathways: serotonin related ( ), glu-np 20
tamate related ( ), dopamine related ( ), adrenergicnp 16 np 3
( ), and neurotrophic ( ), along with selected genesnp 4 np 4
in other pathways ( ). The complete list of genes studiednp 21
is shown in table 2.
Selection of SNP Markers
For each candidate gene, genotype data spanning the coding
region and up to 2 kb of flanking sequence were downloaded
from the International HapMap Project, accessed November
2004.20 Since the STAR*D sample is mostly white, data from
the CEPH sample (Utah residents with northern and western
European ancestry) were used. The program LDSelect21 was
used to select an optimal set of available SNPs to genotype,
at an threshold of 0.8. From the remaining SNPs, we2r
further excluded those with a minor-allele frequency !7.5%,
since we expected the alleles that contribute to treatment out-
come in this data set to be common. Six nonsynonymous SNPs
and four SNPs reported elsewhere22,23 to be associated with
treatment outcome were added to the set, which brought the
total to 768. Illumina then performed a bioinformatic screen
that identified 12 markers that would likely fail in their Bead-
Array assay. Predicted failures were replaced by a nearby marker
that was in strong linkage disequilibrium (LD) with the ex-
cluded SNP, if available. Absent this, a nearby marker with
an allele frequency similar to that of the excluded marker was
selected. The complete list of SNPs genotyped, along with
flanking sequence and expected alleles, is available on request.
Genotyping Methods
Since all of the collected samples were not available at the
start of the experiment, only the first 1,380 samples were shipped
to Illumina, where they were genotyped on the Illumina Bead-
Array platform, a highly accurate, high-throughput assay.24
At Illumina, 99.78% of samples were successfully genotyped,
and 97.92% of SNPs produced usable data, so that a total of
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1,034,602 of a possible 1,035,504 genotypes were returned,
including 11,280 blind duplicate genotypes, all of which
matched exactly.
On the basis of the results of the first 1,380 samples, five
SNPs in the remaining samples were genotyped using Taqman
chemistry, were scored on a fluorescent plate reader (Molecular
Dynamics) without regard to phenotype. By design, 394 sam-
ples were genotyped at rs7997012 and rs1928040 both by
Illumina and in-house (McMahon Lab). No discrepancies were
detected.
Analysis Plan
The primary experiment was based on comparison of allele
and genotype frequencies between subjects who benefited or
did not benefit from citalopram therapy. Because the number
of tests in this experiment was large, a split sample design was
employed. The 1,380 samples genotyped for all SNPs were di-
vided, a priori, into a discovery sample and a replication sam-
ple. The discovery sample consisted of two-thirds of the total
sample genotyped at Illumina; the replication sample consisted
of the remaining one-third. The choice of asymmetric sample
sizes for the discovery and test samples was based on the large
overall sample size. Splitting the sample in this fashion allowed
for the detection of genetic effects of equal size but with a more
conservative nominal significance level in the discovery sample
than in the test sample. The split samples were matched on
sex and reported race (collapsed into “white,” “black,” and
“other/mixed”). Any SNPs meeting the a priori significance
levels in both the discovery and test samples (see below) were
tested for robustness in the total data set.
Power Analysis
The power to detect association was estimated in two ways.
In the first, standard statistical methods25 were used to deter-
mine the effect size for approximate sample sizes for the dis-
covery and replication samples and for a third sample that
included the discovery, replication, and all remaining samples.
The discovery sample was screened with a nominal significance
level of .01, which had a power of 0.9 to detect an allelic effect
size of 0.16. The power to detect a similar effect size in the
smaller replication sample was ∼0.8 at the level.Pp .05
In addition, the power to detect allelic and genotypic (ad-
ditive) effects was estimated for logistic regression analysis for
a variety of genetic models (Quanto v. 1.0 beta [ nvi-Gene#E
ronment, Interaction home page]).26 There areGene#Gene
a large number of possible underlying genetic models. Esti-
mates of power under a specified model are appropriate only
when the specified model is, in fact, the true underlying model.
For example, in an unmatched case-control design (case:con-
trol ratio of 1:0.5), for a log-additive model with allele fre-
quency of .3, a significance level of .01, and a power of .90,
the detectable genetic relative risks for sample sizes of 600 and
300 were ∼1.5 and ∼1.7, respectively. At a power of .80 and
a significance level of .05, corresponding genetic relative risks
were ∼1.4 and ∼1.6, respectively.
Race and Ethnicity
Subjects were enrolled into the STAR*D study without re-
gard to race or ethnicity. Detailed data on ethnicity were not
collected, but most subjects identified themselves as “white,”
“black,” or “other.” We attempted to verify this self-reported
race using STRUCTURE,27 which assigns a probability of group
membership to individuals on the basis of marker-allele fre-
quencies. Since the number of subjects of “other” ethnicity in
the sample was small, they were excluded from the analysis.
We prepared a test data set of 1,284 individuals containing
57 unlinked loci selected from among those genotyped at Il-
lumina, and we ran this in STRUCTURE under an admixture
model with correlated allele frequencies, performing 20,000
burn-ins and 20,000 repetitions. This set of markers robustly
distinguished between black and white subjects in this sample,
with median posterior probabilities of group membership of
0.8 for the black subjects and 0.6 for the white subjects. We
then divided the sample into self-identified whites and self-
identified blacks and ran STRUCTURE again with the same
markers. In each subject, STRUCTURE identified only one
major cluster, and a one-population model gave the best fit to
the data (data not shown).
Statistical Methods
All pairs of individuals were compared using RELCHECK,28
which verified that individuals were unrelated. Because the
sample consisted entirely of patients with major depression, a
marker that increased risk for major depression in many of
these individuals would not necessarily be in Hardy-Weinberg
equilibrium.29 Thus, SNPs were not removed from analysis
because of deviation from Hardy-Weinberg expectations.
Tests of association included the Pearson x2 test ( for2# 2
allelic and for genotypic associations), likelihood-ratio2# 3
x2 test ( for allelic and for genotypic associations),2# 2 2# 3
and Fisher’s exact test ( for allelic associations only).2# 2
Since each test has complementary advantages, all tests were
used to make decisions about replication. This strategy might
increase false-positive results due to multiple testing, but the
high correlation between the tests makes this unlikely. Some of
the SNPs tested had relatively rare alleles, which led to con-
tingency tables with small cell sizes. The Pearson x2 test is only
an approximation for these SNPs but makes no assumptions
about the underlying model. Fisher’s exact test is robust to
small cells but assumes that the marginal distributions of the
contingency table are fixed, which may not hold in this sam-
ple. When small cell size warnings were ignored, correlations
among P values from the Pearson x2, likelihood-ratio x2, and
Fisher’s exact test were high (1 0.9) for the main SNP of in-
terest. Fisher’s exact test was the most conservative of the tests
considered, so those are the findings presented in the “Results”
section. For the quantitative outcome phenotype, genotypic
means were compared with the F test. All P values were from
two-tailed tests. LD between adjacent SNPs was estimated us-
ing Haploview 3.2,30 which generates estimates of D′ and 2r
that are based on the input genotypes.
Results
Marker Coverage
The genotyped SNPs sampled the common variation
within the genes selected for study at a median pairwise
D′ value of 0.81. Overall, 75% of adjacent marker pairs
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Figure 3 Allelic association between treatment outcome and each of 768 SNPs representing 68 candidate genes. Allelic association P
values were ranked in the discovery and replication samples, then the ranks were summed across samples. For visual clarity, the inverse of the
sum of ranks is shown on the Y-axis. The remission phenotype is indicated by the unblackened circles, the response phenotype by the blackened
circles. Only rs7997012 met the a priori P value thresholds in both samples. Another SNP, rs2178865, ranked highly in both samples but fell
short of the a priori significance level in the replication sample.
were in LD at a . Only 5% of SNP pairs were′D 1 0.73
associated with each other at an value of 10.8, dem-2r
onstrating that our SNP-selection strategy effectively ex-
cluded redundant markers.
Allelic Association Results
Each SNP was tested for association with treatment
response and remission in the discovery sample (np
). A total of 12 SNPs met or exceeded the nominal1,380
significance level of .01 for one or both phenotypes. Of
these, only one SNP met or exceeded the nominal sig-
nificance level of .05 in the replication sample for the
same allele and phenotype (fig. 3). This SNP, rs7997012,
resides in the second intron of the gene HTR2A, which
encodes the serotonin 2A receptor. None of the other
767 SNPs met these strict criteria for association and
replication in this experiment.
In HTR2A, significant association was detected, in both
samples, between the same (A) allele of rs7997012 and
treatment response (table 3). (Evidence of association
was also detected between this allele and the remission
phenotype, but this did not meet our a priori significance
levels in both samples.) An additional SNP in HTR2A
(rs1928040) showed evidence of association with re-
sponse and remission in the discovery sample but not in
the replication sample. LD analysis demonstrated that
these two SNPs were not in strong LD with each other
(fig. 4).
On the basis of these results, we genotyped rs7997012
and rs1928040 in the remaining subjects and tested as-
sociation with treatment outcome in the total sample.
Significant evidence of association was again observed
between rs7997012 and treatment outcome (table 3),
with P values on the order of for the treatment610
response phenotype. Evidence of association between
rs1928040 and treatment outcome was not substantially
stronger in the total sample.
Since rs7997012 and rs1928040 are both intronic
SNPs with no known function, we also genotyped two
SNPs in HTR2A (rs6313 and rs6311) that may have
functional importance.31–33 Both SNPs were in tight LD
with each other and with rs1928040, but they were not
in significant LD with rs7997012. Neither rs6316 nor
rs6311 showed significant association with treatment re-
sponse or remission in the total sample (table 3).
Further support for association with rs7997012 was
obtained in the quantitative-trait analysis (table 3). The
marker rs7997012 was significantly associated with rel-
ative change in initial QIDS-C16 score, with a P value
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Table 3
Results of Association Analysis of Genotyped HTR2A SNPs, Stratified by Race
PHENOTYPE AND SNP
ALL WHITE BLACK
N
P
n
P
n
P
Allelewise Genotypewise Allelewise Genotypewise Allelewise Genotypewise
Remission:
rs7997012 1,149 .000024 .000035 911 .00107 .00183 170 NS NS
rs1928040 1,148 .0446 .0701 910 .0626 NS 170 NS NS
rs6313 1,183 NS NS 942 NS NS 172 NS NS
rs6311 1,180 NS NS 939 NS NS 172 .0431 .0874
Response:
rs7997012 1,329 .000037 .000002 1,049 .00183 .000157 199 NS NS
rs1928040 1,327 .0709 NS 1,048 NS NS 199 NS NS
rs6313 1,372 NS NS 1,086 NS NS 202 NS NS
rs6311 1,371 NS NS 1,084 NS NS 203 .0918 .0149
Change in QIDS-C16:
rs7997012 1,749 .000007 .00000146 1,380 .00123 .000516 261 NS NS
rs1928040 1,747 .0214 .0072 1,378 .0738 .0887 261 NS NS
rs6313 1,802 NS .0878 1,425 NS NS 264 NS .0353
rs6311 1,804 .0599 .0494 1,426 NS NS 265 .0094 .0261
NOTE.—SNPs are shown in physical order (by row) within each phenotype. Results were similar when subjects with probable phenotypes
were included (data not shown).
of for allelic and for genotypic5 67.0# 10 1.0# 10
association. Less-significant evidence of association was
also observed at other HTR2A SNPs (table 3).
Stratified Analyses
Having established an association between treatment
outcome and HTR2A in this sample, we next sought to
characterize the association with respect to medication
tolerability and race, using data sets stratified by the
variable of interest. We used rs7997012 as the test SNP
and remission as the outcome variable, since they had
yielded the strongest evidence of association in the earlier
analyses.
In the primary analysis, medication-intolerant subjects
were dropped from the nonremitter and nonresponder
groups. However, this clinically justified decision created
an imbalance with the remitter and responder groups,
which included medication-intolerant subjects. To rule
out any role of this imbalance in the primary association
finding, we dropped the medication-intolerant subjects
from the remitter and responder groups, then reanalyzed
the data. Significant association between rs7997012 and
treatment outcome remained in the sample of medica-
tion-tolerant subjects ( , for5Pp 2.3# 10 np 1,140
the remission; , for the re-5Pp 2.3# 10 np 1,303
sponse phenotypes).
It has been suggested that black patients respond less
well than white patients to antidepressant medications,
particularly SSRIs, but firm data are lacking. When we
divided this sample by race into “white” and “black”
strata, two important differences emerged. First, we noted
that the A allele of rs7997012 that was associated with
better treatment outcome in the mixed-race sample was
more than six times more frequent in the white than
in the black participants (allele frequency in whitesp
, in blacks, 0.06). Second, it was apparent that the0.42
association between HTR2A and treatment outcome was
largely confined to the white participants. No significant
association between rs7997012 and either treatment re-
sponse or remission was detected in the black partici-
pants, although nominally significant results appeared
for rs6313 and rs6311 in some analyses (table 3).
Potential Confounders
Carriers of the A allele of rs7997012 were compared
with the other cases by means of several variables that
could themselves be associated with treatment outcome:
maximum citalopram dose (in mg), tolerability, sex, and
initial QIDS-C16 score. Carriers of the A allele did not
differ from the other cases for any of these variables (data
not shown).
Strength of Association
For treatment-outcome phenotypes, the usual measures
of strength of association, on the basis of odds ratios,
are perhaps less informative than are measures that di-
rectly capture differences in clinical outcome.34 Thus, we
compared the rates of treatment response among par-
ticipants grouped by genotype at rs7997012. Overall,
79.9% of those homozygous for the A allele were clas-
sified as “responders,” compared with 62.4% of those
homozygous for the G allele. Among white participants,
the values were 79.7% and 63.5%, respectively. Thus,
the AA genotype at rs7997013 confers a 16%–18% re-
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Figure 4 Physical positions and LD relationships among SNP
markers genotyped in the STAR*D sample. This figure shows the Ref-
seq gene model for HTR2A taken from the UCSC Genome Browser
(build 43), juxtaposed on a graphical representation of intermarker
values produced by Haploview 3.2.302r
duction in absolute risk of being a nonresponder in this
sample.
Discussion
To our knowledge, this is the first demonstration of sig-
nificant, reproducible association between genetic vari-
ation and outcome of antidepressant treatment. The as-
sociation signal reproduces in both our discovery and
our replication samples and increases in significance with
the inclusion of additional subjects. We evaluated three
related definitions of treatment effectiveness: two cate-
gorical outcomes (response and remission) and a quanti-
tative outcome based on relative change in the final symp-
tom score. The categorical outcomes were defined in a
way that created gaps between responders/remitters and
nonresponders/nonremitters, thus increasing the con-
trast between these groups. The quantitative-trait anal-
ysis (which included all patients) supported the results
of the categorical phenotypes and demonstrated that the
observed association was not a consequence of the ar-
bitrary outcome categories. Furthermore, the HTR2A
allele that was associated with better treatment outcome
was more than six times more frequent in white than
in black participants, who had an overall less favorable
treatment outcome in this sample.12
This study has several limitations and strengths. We
did not perform a complete genomewide association
study, so we cannot conclude that we have found all the
genes that may be relevant to antidepressant-treatment
outcome. Instead, we screened 68 genes selected by an
expert panel as the best candidates. Given the available
marker coverage, we did not sample all common vari-
ation in these genes, but pairwise LD analysis indicated
that much of the common variation was sampled. The
large sample size allowed detection of weak effects with
high statistical confidence, along with replication testing.
The association results, however, do not necessarily point
to functional variants in HTR2A. Our strongest results
are not attributable to either of the suspected functional
variants in HTR2A. Instead, these results point to in-
tronic variants whose functional relevance is unknown.
(Indeed, given the local patterns of LD, we cannot fully
exclude the possibility that the association signal actu-
ally reflects another, nearby gene.) However, our results
set the stage for a focused search for functional variants
in the 3′ end of HTR2A in future studies. We employed
phenotypes on the basis of a uniform rating of clinical
symptoms that allowed for comparatively simple scoring
of treatment outcome. Alternative methods for scoring
treatment outcome exist and could point to different
genes. The STAR*D study employed a naturalistic as-
certainment and treatment protocol. Thus, these results
should have general relevance in the clinic population
but may differ from those obtained in more narrowly
ascertained study groups.
As expected for a single gene, the clinical impact of
HTR2A on treatment outcome is modest. In the total
sample, white subjects homozygous for the allele asso-
ciated with better treatment outcome had an 18% de-
crease in absolute risk of nonresponse to citalopram,
compared with subjects homozygous for the other allele.
Additional alleles predictive of treatment outcome will
need to be discovered before clinically more-relevant ef-
fect sizes are obtainable. In this regard, one pertinent
negative finding should be highlighted. Outcome after
treatment with SSRIs has been most often associated with
variation in the gene encoding the serotonin transporter,
SLC6A4, the primary target of SSRI action (reviewed
by Anguelova et al.35). We found no evidence of associ-
ation among any of the four genotyped SLC6A4 markers
and treatment outcome in these data. Our split sample
design, with a requirement that the same allele show
association with the same phenotype by the same test
in both samples, was implemented as a way to control
for multiple testing but may have reduced the power to
detect modest association signals.36
We found an interesting two-way relationship between
race, HTR2A variation, and treatment outcomes in this
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sample. First, significantly fewer black patients had fa-
vorable treatment outcomes in this study, partly because
of more early dropouts.12 This is consistent with the few
published reports that black patients respond less often
than do whites to antidepressant medications,37 although
the differences have generally been attributed to psycho-
social factors. Second, the association found between
HTR2A and antidepressant outcome in this study was
largely confined to the white subjects. Although the sam-
ple size of the black population was smaller, no trend
of association with rs7997012 was detected for any
treatment-outcome phenotype. Third, the allele that was
associated with better treatment outcome was more than
six times more frequent in whites than blacks in this
sample. These results suggest that genetic variation in
HTR2A should be considered along with psychosocial
factors in attempts to explain racial differences in an-
tidepressant-treatment outcomes.
Genetic variation in HTR2A has been widely impli-
cated in a variety of neuropsychiatric disorders (reviewed
by Norton and Owen38), but it has not been convincingly
demonstrated that it affects antidepressant-treatment out-
come. One previous study found suggestive evidence that
HTR2A was associated with a delayed and sustained
pattern of treatment outcome in a small sample.39 An-
other small study found suggestive evidence that a dif-
ferent SNP in HTR2A was associated with short-term
treatment outcome.40 One study of 443 depressed in-
patients detected a marginally significant association be-
tween HTR2A variants and outcome.41 Finally, one small
study observed differential treatment response in pa-
tients with one or two C alleles of the T102C poly-
morphism rs6311.42
Although the precise molecular mechanisms by which
antidepressants exert their beneficial effects remain to
be fully elucidated, considerable data implicate the se-
rotonergic system.43,44 On the basis of radioligand bind-
ing, signal transduction, and amino acid sequences, 5-
HT effectors currently comprise seven distinct receptors
(5HT1–7). The 5-HT2A, B, and C subtypes are posi-
tively coupled with the enzyme phospholipase C (PLC).45
The 5-HT2A receptors are postsynaptic receptors that
are highly enriched in neocortex and regulate the func-
tion of prefrontal-subcortical circuits implicated in the
pathophysiology of depression.46,47 The 5-HT2A recep-
tors interact with Gq/G11 guanine nucleotide binding
proteins (G proteins) and thereby stimulate PLC to pro-
duce the intracellular second messengers sn-1,2-DAG (an
endogenous activator of protein kinase C) and inositol-
1,4,5-trisphosphate (IP3), which stimulates the release
of Ca from intracellular stores.
Considerable neurobiological data suggest that the 5-
HT2A receptor plays an important role in antidepressant-
drug action. Different classes of antidepressants, including
citalopram, downregulate 5-HT2A receptors in rodent
and primate forebrain within a time frame paralleling
therapeutic effects in humans.44,46,48,49 Selective 5-HT2A
antagonists are effective in animal models of depression,
and antisense oligonucleotides directed against 5-HT2A
receptors regulate the development of depressivelike be-
havior in the learned-helplessness model.50 Although ci-
talopram does not directly bind to 5-HT2A receptors,
several antidepressants do bind 5-HT2A receptors as an-
tagonists, which likely plays an important role in their
therapeutic action.43 Finally, a growing body of work sug-
gests that antidepressants bring about their delayed ther-
apeutic effects by the induction of neuronal plasticity me-
diated by increased expression of brain-derived neuro-
trophic factor (BDNF).47,51,52 In this context, it is note-
worthy that 5-HT2A antagonists block stress-induced
downregulation of BDNF mRNA in rodents.53 Together,
these results suggest that many of the neuroplastic events
believed to underlie the efficacy of SSRIs are mediated,
in part, via 5HT2A receptors.53 Although future studies
are needed to delineate the precise cellular mechanisms
by which the HTR2A SNP described herein affects re-
sponse to the therapeutic effects of citalopram, the new
genetic data presented here, taken together with the ex-
isting neurobiologic findings, make a compelling case for
a key role of HTR2A in the mechanism of antidepressant
action.
In conclusion, this study demonstrates that genetic
variation in HTR2A is reproducibly associated with out-
come of citalopram treatment in a large sample of out-
patients with MDD. This same variation may contribute
to racial differences in outcomes with SSRI treatment.
Further studies are needed to define the functional changes
in HTR2A that account for the association signal in this
sample.
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Web Resources
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